Protective immunity against  infection can be provided by IgG antibodies towards periodate-sensitive or periodate-resistant glycans by unknown
Gong et al. Parasites & Vectors  (2015) 8:234 
DOI 10.1186/s13071-015-0842-1RESEARCH Open AccessProtective immunity against Schistosoma
japonicum infection can be provided by IgG
antibodies towards periodate-sensitive or
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Background: It has been well accepted that glycans present in schistosomes are highly antigenic. However, it is
not clear what kind of worm glycans can affect the infected host to mount IgG responses and whether mounted
anti-glycan IgG responses are protective.
Methods: The contribution of antigenicity by glycans was measured by using competitive ELISA assay in sera from
infected mice and humans. Monoclonal antibodies towards soluble Schistosoma japonicum egg antigens (SjEA)
were generated from SjEA immunizated mice. The expression of glycans on surfaces of cercaria or young worm
and their distributions were examined by immunofluorescence assay. The protective roles of glycans-specific mAbs
were assayed by determination of the worm and egg burden in infected mice.
Results: Both periodate-resistant glycans and periodate-sensitive glycans are antigenic in schistosome infections.
When monoclonal antibodies against either periodate-sensitive or periodate-resistant glycans were administered
prior to schistosome infections in mice, both kinds of anti-glycan antibodies were found to successfully provide
protective immunity to infected mice.
Conclusions: Both periodate-resistant and periodate-sensitive glycans are antigenic, and dominant anti-glycan IgG
responses can play important roles in protective immunity in schistosome infected hosts.
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Schistosomiasis ranks as one of the most important health
problems in developing countries due to global distribu-
tion and parasitic nature of the disease-causing pathogen
schistosome [1]. Current treatments rely primarily on sin-
gle chemotherapy by praziquantel (PZQ), but high rate of
post-treatment reinfection, inability of PZQ treatment to
interrupt transmission and possible occurrence of drug re-
sistance all limit the use of chemotherapy as preventive
measures [2]. As a result, development of effective and* Correspondence: xc9718@hotmail.com
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schistosome infection and to reduce transmission [1].
It has long been established that immunization with
ionizing radiation-attenuated cercariae (RA) provides so
far the best protective immunity in vaccinated rodents
and primates [3,4]. However, this type of vaccine is not
quite feasible for human use due to its complexity and
potential side effects. Attempts have been made to use
vaccines derived from recombinant proteins generated
by prokaryotic expression. In contrast to the high efficacy
seen in RA, few successes have been achieved from recom-
binant vaccine molecules trialed in mice as well as in large
animals, regardless of whether vaccine molecules are
designed toward Schistosoma mansoni, the species
prevalent in Africa, or toward Schistosoma japonicum,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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causes attributing to different efficacies between RA and
recombinant proteins could be due to a lack of epitopes im-
portant for induction of protective immunity when vaccines
are generated by prokaryotic expressing system.
Possible protective epitopes lacked in such polypeptide
vaccines can be glycans which are generated via glycosyl-
ation on proteins or lipids known to heavily occur on
schistosome [7]. Both egg secretions and cercarial secre-
tions of Schistosoma mansoni are found to have high
mannose type, truncated type, complex and hybrid type
of N-glycan structures, as well as mucin-type and novel
type of O-glycan structures [8]. It is not known whether
these abundantly expressed glycans by worms are simply
a disguise to escape host immune surveillance as pro-
posed [9,10], or some of these glycans are in fact in-
volved in induction of protective immune responses. If
the latter is true, glycan epitope is certainly needed to be
considered in anti-schistosome vaccines.
IgG antibodies (IgGs) generated from infection by
Schistosoma mansoni during both early- and egg- stage of
infection are largely directed to glycans because mark-
edly reduced IgGs binding activities are observed on
periodate-treated schistosome antigens compared to
untreated antigens [9,10]. This notion is largely based
on the assumption that periodate treatment will alter
most of glycan-associated epitopes attached to polypep-
tides or lipids, thus periodate-treated glycosylated antigens
are conventionally named as deglycosylated antigens. The
legitimacy of regarding periodate-treated antigens as de-
glycosylated molecules has been questioned [11]. More-
over, it is not clear if dominant anti-glycan IgG responses
found in schistosome infection are associated with pro-
tective immunity.
In this report, we verified that IgGs in sera of Schistosoma
japonicum infected mice and patients are predominantly
targeted to untreated egg antigens (SjEA) with significantly
reduced reactivities against periodate-treated egg antigens
(pSjEA). In contrast to conventional assumption that
periodate treatment will destroy all glycan-associated
eiptopes, our data demonstrated that pSjEA still contained
periodate-resistant sugars by lectin blotting. More import-
antly, the remained IgGs binding activities against pSjEA
present in sera from infected patients and infected mice
were primarily targeted to glycans but not to proteins by
competitive inhibition ELISA assay. Therefore, dominant
anti-glycan IgG responses induced in schistosome infec-
tion should not be explained that IgGs binding activities
on periodate-treated schistosome antigens markedly re-
duced compared to untreated antigens as previous studies
have revealed [9,10]. In fact, both periodate-sensitive and
periodate-resistant glycans are prominently involved in
donating antigenicity in infected host. More significantly,
monoclonal antibodies towards both kinds of glycans wereable to provide protective responses against worm infec-
tion. Results generated from this study provide evidence
on the necessity to include glycans in selection of vaccine




All animal experiments were performed in strict accord-
ance with the Regulations for the Administration of Affairs
Concerning Experimental Animals (approved by the State
Council of People’s Republic of China) and the Guide for
the Care and Use of Laboratory Animals (Experimental
Animal Center, Tongji University, certificated by Shanghai
Committee of Science and Technology). All procedures
performed on animals in this study were approved by the
Committee on the Ethics of Animal Experiments of Tongji
University (Permit Number: TJLAC-009-031).
Mice and parasites
6–8 weeks old female Balb/c mice were purchased from
SLAC laboratory (Shanghai, China). All mice were main-
tained under specific pathogen-free conditions and fed
with standard laboratory food and water. Gender and age-
matched mice were infected percutaneously with 30 ± 2
cercariae of Schistosoma japonicum, which were shed
from infected Oncomelania hupensis snails provided by
the National Institute of Parasitic Diseases at Shanghai,
China. Young worms were recovered from hepatic portal
vein of infected mice perfused by cold PBS pumped into
the aorta artery 18 days post-infection. Both cercariae and
worms will be used in immunofluorescence assay.
Preparation and treatment of soluble egg antigens from
Schistosoma japonicum
Soluble Schistosoma japonicum egg antigens (SjEA) were
prepared as described with modifications [12]. Purified
eggs were crushed with ultrasonication for 10s each run
with interval break of 10s for 30 min in cold PBS. After
being centrifuged at 13,000 rpm for 30 min, the superna-
tants were filtered through 0.22 μm filters and stored at-
80°C until use.
Periodate oxidation was performed as described [13].
10 mM sodium metaperiodate (Sigma) was added to
SjEA (2 mg/ml) dissolved in 50 mM sodium acetate buf-
fer (pH 4.6) for 45 min. Oxidation reaction was stopped
by adding sodium borohydride with final concentration
at 50 mM. Mock-treated SjEA was subjected to the same
procedure with omission of sodium metaperiodate treat-
ment. After reaction, mock- or periodate-treated SjEA was
extensively dialyzed against PBS and the concentration was
readjusted based on protein concentration measured by
Bradford method (Bio-Rad). The effects of metaperiodate
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WGA and anti-Lewisx staining as shown in Figure 1.
To release N-glycans from protein backbone, SjEA
was enzymatically digested with PNGase F (NEB) as
instructed by manufacturer’s protocol. Briefly, SjEA was
denatured by heating at 100°C for 10 min in glycoprotein
denaturing buffer (NEB). After cooling, PNGase F was used
to remove N-linked oligosaccharides by incubation at 37°C
in G7 Reaction Buffer (NEB) supplemented with 1% NP40Figure 1 Inhibitory effects on IgGs binding activities by egg antigens devo
antigens (SjEA) than against periodate-treated SjEA (pSjEA) were found in s
(B). Data shown were mean ± SEM of OD values of variously diluted sera in
representative of two separate experiments. C. SjEA devoid of proteins
capable of inhibiting IgG bindings with SjEA whether in infected mice o
competitive inhibition curve on IgGs in infected sera was shown on pa
control for inhibition assay and OVA as negative control. A summary on
infected humans (n = 7) by proteinases-treated SjEA was shown at panel 2 an
capable of inhibiting IgG bindings with pSjEA at dose-dependent fashion. A r
shown on panel 1 (mouse) and panel 3 (human) using untreated pSjEA as po
on calculated percentage of inhibition from infected mice (n = 5) or infected
panel 4. E. Con A, WGA and anti-Lewisx antibody staining of mock- and perio
to analyze the significance of percent inhibition with *** as p < 0.001.for 48 h. Mock-treated antigens were obtained by the same
procedure without addition of enzymes.
To digest proteins, SjEA or pSjEA was treated by pro-
teinase K (Tiangen Biotech, China) at 56°C overnight,
followed by heat inactivation of enzymes at 100°C for
10 min. In order to fully hydrolyze peptide, carboxypep-
tidase Y (Sigma) was subsequently used to digest pro-
teinase K-treated SjEA or proteinase K-treated pSjEA at
25°C overnight with heat inactivation. Mock treatmentid of proteins. A and B. Higher levels of IgG against untreated egg
era from Schistosoma japonicum infected mice (A) or infected humans
infected mice (n = 5) or in infected patients (n = 7). Data on mice were
by proteinase K (PK) and carboxypeptidase Y (CPD Y) treatment was
r infected humans at dose-dependent fashion. A representative
nel 1 (mouse) and panel 3 (human) using untreated SjEA as positive
calculated percentage of inhibition from infected mice (n = 5) or
d panel 4. D. pSjEA devoid of proteins by proteinases treatment was also
epresentative competitive inhibition curve on IgGs in infected sera was
sitive control for inhibition assay and OVA as negative control. A summary
humans (n = 7) by enzyme-treated pSjEA was shown at panel 2 and
date-treated SjEA. Anti-GST was used as loading control. t test was used
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ure without addition of enzymes. Protein disruption was
regularly checked by SDS-PAGE viewed by silver staining.
Generation of monoclonal IgGs against SjEA
Mice were injected subcutaneously with 100 μg SjEA
formulated in CFA for primary immunization followed
by boosting immunization twice with 50 μg SjEA formu-
lated in IFA with 2 weeks interval. Hybridomas by fusing
B cells from splenocytes with myeloma cells were made
following standard procedures by Abgent (China), and 3
hybridoma cell lines were obtained based on their stable
growth and on high IgG binding activities with SjEA.
Large quantity of mAbs was generated from ascitic
fluids in Balb/c mice that were injected with 200 μl IFA
intraperitoneally 1wk before 5 × 106 monoclonal hybridoma
cells were injected into peritoneal cavity. Ascites began to
be harvested around 10th day after injection of cells. The
IgGs in collected ascites were affinity purified and enriched
through protein G-Sepharose column (Pointbio, China).
The purity of mAb was determined by SDS-PAGE by sliver
staining; the antibody titer was determined by its reactivity
with SjEA by ELISA, and anti-glycan nature of IgG anti-
bodies was determined by competitive ELISA.
Measurement of anti-glycan IgGs in sera and in monoclonal
antibodies with ELISA
Levels of anti-SjEA IgG was determined as described by
ELISA [12]; whereas detection of anti-pSjEA IgG anti-
bodies was performed with periodate treatment of egg
antigens being carried out in plates as described [10].
Plates were coated overnight with 5 μg/ml of SjEA in
carbonate-bicarbonate buffer (pH9.6). After being washed
twice with 0.05 M sodium acetate (pH 4.6), 100 μl so-
lutions containing 10 mM sodium-periodate dissolved
in 0.05 M sodium acetate or containing 0.05 M so-
dium acetate were added to SjEA coated in wells for
1 h at 37°C to make pSjEA. After washing plates with
sodium acetate twice and with PBS once, the plates
were treated with 50 mM sodium borohydride in PBS
for 30 min at room temperature to stop periodate re-
action. Mock-treated SjEA was subjected to the same
procedure without sodium-periodate treatment. Plates
were then extensively washed by PBS containing 0.05%
Tween-20 (PBST) for 5 times and blocked with PBST
containing 3% BSA for 1 h at 37°C. Sera or monoclo-
nal antibodies were added at appropriate dilutions and
incubated for 2 h at 37°C. After plates were washed
with PBST, HRP-labeled goat anti-mouse IgG (H + L) was
added at 1:10000 and incubated for another 1 h at 37°C.
Final color development was achieved by addition of
ABTS (2, 2′-Azino-bis (3-Ethylbenzthiazoline-6-Sulfonic
Acid) (Sigma) with absorbance at 405 nm by plate reader
(Thermo scientific) after plates being extensively washed.Endpoint titers are defined as the lowest antibodies dilu-
tion which gives rise to an average OD that is 2.1 times
greater than that of PBS.
The sera from infected mice were collected six weeks
after Schistosoma japonicum infection. Human sera from
7 normal subjects and 7 patients who were positive for eggs
in the feces by Kato-Katz test were kindly provided by the
Institute of Infectious Disease and Vaccine Development,
Tongji University. The detection was made by HRP-
conjugated anti-human IgG (Promega) diluted at 1:10000.
Anti-glycan nature of IgG antibodies was determined
by competitive inhibition assay through ELISA by pro-
teinase K and carboxypeptidase Y-treated antigens. Sera
or monoclonal antibodies with appropriate dilution were
mixed first with serially diluted various kinds of antigens
including mock SjEA or pSjEA, proteinase K-treated
SjEA or pSjEA, proteinase K and carboxypeptidase Y-
treated SjEA or pSjEA and OVA as irrelevant protein
control for 2 h at room temperature before they were
added onto SjEA- or pSjEA-coated plates. After incuba-
tion for 1 h at 37°C, protocol for ELISA described above
was followed. Anti-glycan nature is indicated if the bind-
ing of IgGs with SjEA or pSjEA can be competed away
by prior incubation with enzyme-treated SjEA or pSjEA.
Percent inhibition due to presence of pretreatment with the
maximal dose of treated egg antigens was calculated as fol-
lowing: percent inhibition = (OD without pretreatment −
OD with pretreatment) / (OD 405 without pretreatment −
OD blank) × 100.
Immunofluorescence staining by monoclonal antibodies
on worms
Monoclonal antibody was diluted in PBST containing 5%
(w/v) BSA. 18 days old young worms and fresh cercariae
of Schistosoma japonicum were fixed by 4% paraformal-
dehyde for 2 h. After being blocked with 5% BSA in PBS
for 1 h at room temperature and washed three times
with PBST, whole-mount cercariae or young worms
were incubated with monoclonal antibody diluted at
2 μg/ml overnight at 4°C. After being washed in PBST,
FITC-conjugated goat anti-mouse IgG (H + L) (1:400,
KPL) was added for 30 min at room temperature in the
dark. The slides were mounted with Antifade Mounting
Medium (Beyotime Institute of Biotechnology, China).
Images were acquired on confocal laser scanning micro-
scope (Leica). Normal mouse IgG was used as negative
control for staining.
Protective immunity by passively transferred monoclonal
IgGs
Female Balb/c mice were challenged with 30 ± 2 Schisto-
soma japonicum cercariae via abdominal skin penetration.
One day before and 14 days after infection, 100 μg mo-
noclonal antibodies were administered intraperitoneally.
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burdens as described [14,15]. Briefly, 42 days after chal-
lenge, all mice were euthanized. Both male and female
adult worms were collected and counted by perfusing
mice with cold PBS from mesenteric veins. Meanwhile,
livers were isolated, weighed, minced and digested in
10 ml of 4% NaOH at 55°C for 2 h. Schistosome eggs
released from infected livers were counted in 10 μl ali-
quots by light microscopic examination. Three aliquots
were counted per liver sample and the average numbers
were used as the egg burdens in each infected mice. Ex-
periments were conducted for three times on different
dates with different batches of cercariae and different
batches of monoclonal antibodies generated.
Statistical analysis
Unpaired Student’s t test and one-way ANOVA were
used to determine statistical significance of differences
among groups.
Results
IgGs from Schistosoma japonicum infected mice and
patients demonstrated binding activities to both
periodate-sensitive and periodate-resistant glycans
The IgG responses towards schistosome egg antigen-
associated glycans were investigated on sera obtained
from Schistosoma japonicum infected mice and humans
via competitive ELISA assay using proteinase K and car-
boxypeptidase Y-treated egg antigens. As reported [9,10],
IgGs from infected mice or humans were found to bind
significantly less with periodate-treated egg antigen
(pSjEA) than with mock-treated egg antigen (SjEA) by
ELISA (Figure 1A and B). To determine whether glycans
on egg antigens contribute to IgG binding reactivities with
untreated SjEA, competitive ELISA assay is used to meas-
ure loss of IgG binding activities with egg antigens if opti-
mally diluted sera is pre-incubated with antigens devoid of
proteins by proteinase K and carboxypeptidase Y treatment.
As shown in Figure 1C, comparing to inhibition by differ-
ent doses of untreated SjEA, proteinase K-treated SjEA as
well as proteinase K and carboxypeptidase Y-treated SjEA
were able to inhibit IgGs binding activities with SjEA
almost as much as untreated SjEA when infected human
sera were examined. When similar inhibition assay was per-
formed on IgGs from infected mice, about 50% reduction
was consistently observed by proteinase K and carboxypep-
tidase Y-treated SjEA.
Competitive ELISA assay was then used to measure the
remaining binding activities of IgGs towards pSjEA, we
unexpectedly found that pSjEA treated by proteinases was
still able to inhibit IgGs binding with pSjEA almost as
much as untreated pSjEA both in infected mice and in in-
fected humans (Figure 1D). This particular finding
strongly indicated that periodate treatment in fact doesnot totally destroy glycan epitopes as believed [9,10].
Indeed, glycans positive for lectin WGA binding were
still observed in periodate-treated SjEA, although glycans
positive for ConA or for anti-LewisX antibodies were
both diminished (Figure 1E). More importantly, it in-
dicated that some of these periodate-resistant glycans ac-
tually contribute to antigenicity or immunogenicity of egg
antigens for induction of IgG response in Schistosoma
japonicum infection. It is both periodate-sensitive and
periodate-resistant glycans that together confer glycan-
associated dominant IgG responses seen in schistosome
infection.Both periodate-sensitive and periodate-resistant
glycan-specific monoclonal antibodies were successfully
generated from SjEA immunized mice
To better study glycan antigenicity in egg antigens, mono-
clonal antibodies were generated from Balb/c mice immu-
nized with SjEA emulsified in complete freund’s adjuvant.
We obtained three hybridoma clones which can stably
secrete high levels of SjEA-specific IgGs with isotype de-
fined as IgG1. The endpoint titer of IgGs from these 3
clones named as 161.68, 517.77 and 524.30 respectively was
high to 409,600, 25,600 and 12,800 (Figure 2A).
The periodate-sensitive or periodate-resistant nature
of glycan epitopes recognized by monoclonal antibodies
were then determined by ELISA assay with egg antigens
treated with periodate or enzymes. Recognition of SjEA
by mAb 161.68 was resistant to periodate treatment
(Figure 2B). Furthermore, the bindings between SjEA
or pSjEA and mAb 161.68 were all counteracted at similar
levels by proteinase K and carboxypeptidase Y-treated egg
antigens compared to untreated egg antigens (Figure 2C).
On the other hand, recognition of SjEA by mAb 517.77
and 524.30 was sensitive to periodate treatment (Figure 2B),
proteinase K and carboxypeptidase Y-treated SjEA was only
able to counteract the bindings between 517.77 and SjEA
but not between 524.30 and SjEA (Figure 2C). Contribution
of N-glycan to epitopes recognized by mAbs was directly
assessed by PNGase F treatment, which has been applied to
release N-glycans on egg antigens [8]. The effectiveness of
enzyme treatment on SjEA was demonstrated on loss of
ConA recognition [16] as shown in Figure 2D. After egg
antigens were digested by PNGase F, markedly reduced
levels of detection of SjEA were found when probed by
161.68 and 524.30 comparing to mock-treated SjEA. In
contrast, no changes were found when probed by 517.77
(Figure 2D).
Therefore, monoclonal antibodies of 161.68 likely recog-
nize periodate-resistant N-glycan-associated epitopes; mo-
noclonal antibodies of 517.77 likely recognize periodate-
sensitive glycan epitopes, and monoclonal antibodies of
524.30 may recognize protein-glycan-conjugated epitopes.
Figure 2 Characterization of anti-glycan natures on monoclonal antibodies. A. The bindings of monoclonal antibodies with SjEA were
measured by ELISA and presented as mean ± SEM of the OD values from triplicate wells at different dilutions. B. Comparison of bindings
of monoclonal IgGs with SjEA versus with pSjEA by ELISA. t test was performed on mean values obtained from triplicate wells from
single experiment with *** as p < 0.001. C. Inhibitory effects on bindings of monoclonal antibodies by egg antigens devoid of proteins.
Similar methods were applied as in Figure 1C and D. Data shown were mean ± SEM values from triplicate wells. D. Mock- treated (lane 1)
or PNGase F-treated egg antigens (lane 2) were detected by monoclonal antibodies with western blot analysis. HRP-ConA was used to
test the effect of PNGase F digestion on SjEA and anti-GST was used as loading control. Shown was a representative of at least three
separate experiments.
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glycan-specific monoclonal antibodies provide protective
immunity towards Schistosoma japonicum infection in mice
Surface-exposed antigens on cercaria and schistosomula
are commonly believed to be valid antigens to be targeted
for establishment of effective antibody-mediated protective
immunity against worm infection [17,18]. Immunofluores-
cence staining was performed to quest if these monoclonal
antibodies towards egg antigen-associated glycans can also
recognize glycan antigens on cercariae or young worms
and their distributions. The results showed that positive im-
munostaining by 517.77 was found at the surfaces of cer-
cariae as well as on surfaces of young worms. The positive
staining by 161.68 was mainly distributed at the surfaces of
young worms. 524.30 and mouse IgG, however, failed to
demonstrate any significant staining on surfaces of cer-
cariae or young worms examined (Figure 3A). Thus, mono-
clonal antibodies obtained against either periodate-sensitive
or periodate-resistant glycans also recognize surface glycan
antigens on cercariae or young worms which are cross-
reactive with egg glycans.
The effects of anti-glycan IgG antibodies in protective
immunity were assessed by administration of monoclonal
antibodies prior to infection with mouse IgG as control. All
3 monoclonal antibodies and mouse IgG were individually
given at 100 μg each time intraperitoneally 1 day before
and 14 days after Schistosoma japonicum infection. Forty
two days after infection, the number of worms recovered
from mesenteric vessels and the number of eggs recovered
from livers were counted and compared among different
treatment groups. There were no significant differences
among treatments by normal mouse IgG, by 524.30 and
without treatment in terms of worm burden and egg num-
bers recovered (Additional file 1: Figure S1). However,
treatment of mice with either 161.68 or 517.77 provided
statistically significant protective responses to the infected
mice, in that worm burden was reduced by 31.22% and
28.57% respectively and egg numbers in livers were re-
duced by 31.83% and 34.96% (Figure 3B). No protective
effects were seen when doses of monoclonal antibodies
given were reduced in half (Additional file 2: Figure
S2). Furthermore, egg burdens were not disproportion-
ately reduced compared with burdens of worms, sug-
gesting parasite fecundity was not greatly affected.
Thus, both anti-periodate-sensitive glycan antibodies
and anti-periodate-resistant glycan antibodies can pro-
vide some level of protection to infected hosts.
Discussion
Antigens treated by periodate oxidation have been
widely accepted as deglycosylated antigens with loss of
glycan-determined antigenicity. Such assumption has fa-
cilitated conclusions made by these studies [9,10] that
IgGs elicited in schistosome infections are mainly againstglycans. Our results are in agreement with the conclu-
sions via more thoroughly investigated mechanisms.
We used proteinase K-treated antigens in competitive
ELISA in order to elucidate glycan contribution on antige-
nicity or immunogenicity. We found that predominantly
occurred anti-SjEA IgG responses compared to anti-pSjEA
IgG responses were largely due to IgG reactivities with anti-
genic periodate-sensitive glycans, especially so in infected
humans. Moreover, residual anti-pSjEA IgG responses were
almost derived from antigenic periodate-resistant glycans.
Therefore, the dominant anti-glycan IgG responses found
in schistosome infected mice as well as in infected humans
are not simply resulted from reduced reactivities with
periodate-treated antigens as believed [9,10], but rather a
collective consequence from dominant antigenicity con-
ferred upon by both periodate-sensitive and periodate-
resistant glycans.
Different sugar moieties are reported to possess different
sensitivities towards periodate treatment [11]. Fucose and
sialic acid are mostly destroyed by periodate oxidation,
whereas mannose, galactose and N-acetylgalactosamine are
partially sensitive. Destruction of fucose in periodate-
treated antigens indicates that fucose-conjugated glycocon-
jugates including both glycoproteins and glycolipids may
contribute to dominant IgG responses towards periodate-
sensitive glycans. Several mono- or multiple-fucosylated
LDN (GalNAc (β1, 4) GlcNAc) variants are found to be
highly targeted by IgGs from Schistosoma mansoni infected
individuals [19]. These structures include FLDN (Fuc
(α1-3) GalNAc (β1-4) GlcNAc), LDNF (GalNAc (β1- 4)
(Fucα1-3) GlcNAcβ1) and FLDNF (Fuc (α1-3) GalNAc
(β1-4) [Fuc (α1-3)] GlcNAcβ1). Considering LDNF can
also be expressed by mammalian hosts [20-22], it is likely
that fucose-containing elements FLDN and FLDNF may
contribute more to antigenic periodate-sensitive epitopes in
egg antigens. The other fucose-containing structures
considered as periodate-sensitive antigens should be
LewisX elements (Gal (β1-4) [Fuc (α1-3)] GlcNAc), par-
ticularly the multimeric forms of LewisX which are
known to be expressed in schistosome but less in mam-
malian hosts [8,23,24]. In terms of periodate-resistant
glycan epitopes, it is noteworthy to mention that N-
acetylglucosamine is reported to be largely resistant to
periodate oxidation [11]. Meanwhile, LDN (GalNAc
(β1-4) GlcNAc) which contains N-acetylglucosamine
without fucose has been repeatedly shown to be anti-
genic but not as much as its fucose derivatives in
infected animals and humans [16,19,25]. Although like
LDNF, LDN is also found to be expressed by mamma-
lian hosts [20-22], we cannot exclude the possibility
that LDN can contribute to periodate-resistant glycans-
associated antigenicity demonstrated in present study.
It has been a long sought-after answer whether anti-
glycan IgG or IgE responses developed in schistosome
Figure 3 Anti-glycan monoclonal antibodies provide protective immunity towards Schistosoma japonicum infection in mice. A. Immunofluorescence
localization of antigens recognized by mAbs on cercaria and young worm of Schistosoma japonicum. Normal mouse IgG was used as negative control.
B. Combined results from 3 separate animal experiments were shown on worm and egg burdens in infected mice treated with mAbs of 161.68 (n = 35),
517.77 (n = 33), 524.30 (n = 29) and mouse IgG (n = 33). EPG stands for the number of eggs per gram of liver tissue. One-way ANOVA was used to analyze
the significance with *** as p < 0.001.
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antibody against an undefined 38 Kd Schistosoma man-
soni surface antigen has been found to confer protective
immunity when given before schistosome infection.
Since the binding of this particular monoclonal antibody
to 38 Kd antigen can be competitively inhibited by pres-
ence of KLH but not deglycosyalted KLH, thus it has
been concluded that anti-glycan IgG may provide pro-
tective immunity [27,28]. Our results, however, more
directly demonstrated that anti-glycan IgG responses,
whether towards periodate-sensitive glycans or towards
periodate-resistant glycans, can be protective.
It is intriguing then that schistosome infection always
progresses even though high levels of anti-glycan IgG
responses are seen during natural infection or egg vac-
cination [9,29]. Many factors may attribute to lack of
apparent protective immunity in natural infection with
ongoing dominant anti-glycan IgG responses. Firstly,
the anti-glycan IgGs induced in natural schistosome in-
fections are not represented or under-represented by
relevant protective glycan epitopes. Two different patterns
are detected by protective monoclonal antibodies in present
study. The antigen recognized by 161.68 was about 95 Kd
in size; whereas 517.77 recognizes many bands including a
prominent band above 170 Kd (Figure 2 and Additional file
3: Figure S3). When we attempted to reprobe by infected
sera the protective epitopes in egg antigens immunoprecipi-
tated by protective anti-glycan monoclonal antibodies
161.68, no bindings were detected (Additional file 3: Figure
S3, A1 vs C1). Therefore the protective epitope recognized
by 161.68 is not likely the immunodominant epitope
occurred in natural infection. Secondly, the level of
IgGs against protective epitope is not high enough.
This cause can be seen when molecules pulled down by
517.77 were reprobed with infected sera. The binding
intensities on the antigen above 170 Kd were markedly
reduced (Additional file 3: Figure S3, B2 vs C2). Fur-
thermore, a dose-effect relationship was observed that
protective effects from anti-glycan mAbs were reduced
when the amount of mAb administered was reduced to
half (Additional file 2: Figure S2). Thus, we believe that
protective immunity found by direct anti-glycan anti-
bodies transfer prior to worm infection in this study
may reflect an amplification of the protective immune
response determined by protective glycan epitopes
which is induced at insufficient levels during natural
infection or egg vaccination.
It is not clear how anti-glycan antibodies mediate reduc-
tion of adult worms hence egg numbers. Complement- or
antibody-dependent cell-mediated cytotoxicity of schistoso-
mula may be important pathways to reduce worm burdens
found in this study, since both anti-glycan monoclonal anti-
bodies selected are able to recognize surface antigens on
young worms although they were originally generatedagainst egg antigens. Indeed, a monoclonal antibody to
LDN is reported to be capable of efficiently killing schisto-
somula in vitro via activation of complement cascade [7].
Regardless of what the mechanisms are, the results pre-
sented in this study certainly guarantee important roles
played by some glycan epitopes in conferring protective im-
munity against schistosome infection, and probably against
worm infection in general. Anti-glycan response should not
be considered solely as a smoke screen [26]. This may be-
come more critical when we found that anti-glycan IgG re-
sponses wane during late stage of infection [Additional file
4: Figure S4], similar as reported [9,16]. Therefore, protect-
ive anti-glycan IgG responses, if there is any, appear to
mainly function at early stage of schistosome infection. All
together, it strongly points to the importance to include
worm-specific protective glycan epitopes in vaccine candi-
dates instead of simply using polypeptides generated by
prokaryotic system.Conclusions
In summary, present study reported both periodate-
sensitive glycans and periodate- resistant glycans are
antigenic in Schistosoma japonicum infection. More
importantly, we demonstrated that both kinds of anti-
glycan responses can be protective using the monoclonal
antibodies generated. Further identification of the molecu-
lar basis of protective epitopes will facilitate our under-
standing on mechanisms between host-worm interplay and
on mechanisms of protective immunity induced by glycans.
All these will provide novel targets for vaccines against
schistosome infection.Additional files
Additional file 1: Figure S1. Worm and egg burdens of infected mice
treated by normal mouse IgG (n = 10), 524.30 (n = 10) and untreated (n = 10).
One-way ANOVA was used to analyze the significance with ns as p >0.05.
Additional file 2: Figure S2. Worm burdens of mice passively
administered with mAbs of 161.68 (n = 9) and 517.77 (n = 9) at 50 μg and
control IgG at 100 μg (n = 10). One-way ANOVA was used to analyze the
significance with ns as p >0.05.
Additional file 3: Figure S3. Different patterns between sera from
infected mice and protective monoclonal antibodies to recognize the
antigens immunoprecipitated by 161.68 and 517.77. Relevant antigens
from SjEA co-immunoprecipitated with mAbs 161.68 (lane 1) and 517.77
(lane 2) were reprobed by 161.68 mAbs (A), 517.77mAbs (B) and sera
from infected mice (C). Sizes shown are in kDa.
Additional file 4: Figure S4. ELISA analysis of anti-peptide nature of
IgGs in sera from 11w infected mice. The levels of anti-SjEA and anti-pSjEA IgG
in sera from Schistosoma japonicum infected mice on 77 day (A). Differently
treated SjEA or pSjEA competes IgG bindings with SjEA (B) or with pSjEA (C) in
sera from 11w infected mice. ELISA data shown is one representative animal
from 3 independent mice.Abbreviations
SjEA: Soluble Schistosoma japonicum egg antigens; pSjEA: Periodate
treated- soluble Schistosoma japonicum egg antigens.
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